过氧化物酶体增殖物激活受体γ激活剂吡格列酮对血液透析患者的非降糖作用  

Effects of peroxisome proliferator-activated receptor-γ agonist pioglitazone beyond glucose lowering effect in hemodialysis patients

作　　者：姜惠芳[1] 彭兰芬[1] 肖长长[1] 李强[1] 罗忠明[1] 胡志辉[1] 骆九源[1] 刘兰霞[1] 张月[1] 李桂兰[1] 

机构地区：[1]东莞市厚街医院肾内科,523945

出　　处：《国际移植与血液净化杂志》2014年第3期45-47,共3页International Journal of Transplantation and Hemopurification

摘　　要：目的 探讨过氧化物酶体增殖物激活受体γ（PPARγ）激活剂吡格列酮对血液透析患者的非降糖作用.方法 33例血液透析患者应用吡格列酮（30 mg/d）治疗,分别于用药前、用药4和8周后观察血浆白细胞介素6（IL-6）、高敏C反应蛋白（hs-CRP）、血管紧张素Ⅱ（AngⅡ）、血脂和血压水平.结果 用药4和8周后患者IL-6、hs-CRP和AngⅡ明显低于治疗前（均P＜0.05）;用药8周后血浆总胆固醇（TC）水平明显上升,与用药4周比较差异有统计学意义（P＜0.05）.用药4周后收缩压和舒张压明显下降,与用药前比较差异均有统计学意义（P＜0.01）;用药8周后收缩压明显上升,与用药4周比较差异有统计学意义（P＜0.01）.结论 PPARγ激活剂吡格列酮对血液透析患者具有抗炎、抑制AngⅡ、抗高血压和调节血浆胆固醇等非降糖作用.Objective To investigate the effects of peroxisome proliferator-activated receptor-γ （PPARγ） agonit-pioglitazone beyond glucose lowering effect in hemodialysis patients.Methods Thirty three patients with end stage renal disease on regular hemodialysis were treated with pioglitazong （30 mg/d） for 8 weeks.The plasma level of interleukin 6 （IL-6）,high sensitive C-reactive protein （hs-CRP）,angiotensin Ⅱ （Ang Ⅱ）,lipid profile,systolic pressure （SBP） and diastolic pressure （DBP） were observed before and after 4 weeks （4W） and 8 weeks （8W）.Results IL-6 decreased significantly after 4W and 8W of the therapy （P ＜ 0.05）.Hs-CRP and Ang Ⅱ decreased significantly after 4W and 8W,respectively （P ＜0.01）.Total cholesterol （TC） increased significantly after 8W（P ＜ 0.01）,but it was still in the normal range.SBP decreased significantly after 4W （P ＜ 0.01）,but it increased significantly after 8W （P ＜0.01）.DBP decreased significantly after 4W（P ＜ 0.01）.Conclusions PPARγ agonit-pioglitazone has effects of antiinflammation,inhibiting angiotensin Ⅱ,antihypertension and regulating total cholesterol beyond glucose lowering effect in hemodialysis patients.

关 键 词：过氧化物酶体增殖物激活受体 肾透析 白细胞介素-6 C反应蛋白质 

分 类 号：R459.5[医药卫生—治疗学]